Alembic Pharmaceuticals receives USFDA Final Approval for Chlorthalidone Tablets
Chlorthalidone Tablets USP, 25 mg and 50 mg, have an estimated market size of US $37 million for twelve months ending June, 2022 according to IQVIA
Chlorthalidone Tablets USP, 25 mg and 50 mg, have an estimated market size of US $37 million for twelve months ending June, 2022 according to IQVIA
New mass spectrometry instrument and consumables launch during IMSC 2022
he approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Hygroton Tablets, 25 mg and 50 mg, of Sanofi Aventis US. LLC (Sanofi).
The RRA was conducted from 22nd August, 2022 to 26th August, 2022.
With the receipt of the EIR, the inspection stands successfully closed.
Granules now have a total of 51 ANDA approvals from US FDA (49 Final approvals and 2 tentative approvals).
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
Collaboration supports multiple discovery efforts, including vaccines
Subscribe To Our Newsletter & Stay Updated